Top 10 CROs in Europe – 2024
Contract Research Organisations (CROs) in Europe are navigating a dynamic landscape shaped by transformative technology trends. A significant development is the shift towards digital health solutions, underscored by the integration of technologies such as artificial intelligence (AI), machine learning and big data analytics. These advancements are enabling CROs to enhance clinical trial designs, improve patient recruitment strategies and streamline data analysis processes, increasing efficiency and reducing the time to market for new therapies.
The application of blockchain technology and cybersecurity measures is also becoming increasingly prevalent among European CROs. Blockchain is revolutionising data integrity and security in clinical trials, facilitating secure, transparent and tamper-proof data sharing among stakeholders. In tandem, robust cybersecurity practices are essential in safeguarding sensitive clinical data against burgeoning cyber threats, ensuring compliance with stringent regulatory requirements. Together, these technological adoptions are not only driving innovation in clinical research but fostering trust and reliability in CRO operations.
With the market for CRO services projected to reach $129.8 billion by 2029 from $82.0 billion in 2024, their role in expediting drug development and research processes is undeniable.
One standout factor behind the surge in demand for CRO services is the increase in merger and acquisition (M&A) activities by companies. Larger CROs are actively engaging in M&A to consolidate their position, improve service capabilities and expand geographic reach.
This edition of Life Sciences Review Europe brings insights into the latest developments of CROs and how companies align with the latest trends in the services.
It features a thought leadership article from Matt Pugh, Ph.D., SVP of medical and scientific services at Ashfield MedComms, an Inizio Medical Company, who shares his insights on the importance of medical affairs in strategically supporting research and development (R&D) and commercialisation teams. It also features an article from Piero Rijli, corporate director, of regulatory activities and market access at MENARINI Group, who shares his view on the escalating challenge of antimicrobial resistance. He emphasises the urgent need for comprehensive economic evaluations of antibiotics, considering their societal value beyond direct healthcare costs.
In this edition of Life Sciences Review Europe, we also bring you the story of the top CROs delivering innovative solutions. One of them is RQM+, a CRO provides comprehensive support to manufacturers of all scales across various regions through the entire product lifecycle. The focus is to streamline the clinical research process and enables clients to focus on innovation.In this edition featuring the Top CROs in Europe 2024, we hope you find the right partner to meet your organisation’s needs.
Nominate a Company
Usually, the qualified subscribers of our magazine nominate companies with whom they have collaborated and experienced exceptional results to be in this list. Did a company you recently worked with give you stellar results and ROI? Did it turn out to be one you would wholeheartedly recommend to peers? Or do you know of such an outstanding company through your network? Please fill in the details below and nominate them to be featured here.
Top CROs in Europe
